Conference call scheduled for Thursday, May 29, 2025, at 8:30 a.m. ET Tel Aviv, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR), a global provider of web data collection solutions, will release its financial results for the first quarter ended March 31, 2025, before the Nasdaq market opens on Thursday, May 29, 2025. Mr. Shachar Daniel, Chief Executive Officer, and Mr. Shai Avnit, Chief Financial Officer, will host a conference call on May 29, 2025, at 8:30 a.m. ET to ...

ROUGEMONT, Quebec, May 08, 2025 (GLOBE NEWSWIRE) -- Lassonde Industries Inc. (TSX: LAS.A) ("Lassonde" or the "Corporation") is pleased to announce that it will host a conference call to discuss its first quarter 2025 results on Friday, May 9, 2025. Mr. Vince Timpano, Chief Executive Officer, and Mr. Eric Gemme, Chief Financial Officer, will host the call. OPEN TO:Investors, analysts, and all interested partiesDATE:Friday, May 9, 2025TIME:8:30 a.m. ETCALL:647-846-8280 (for overseas participants)1-833-752-354 ...

Company Overview - VerifyMe, Inc. (NASDAQ: VRME) specializes in providing logistics for time and temperature sensitive products, as well as brand protection and enhancement solutions [3]. Financial Results Announcement - The company will release its financial results for the first quarter ended March 31, 2025, on May 13, 2025 [1]. - An investor conference call and webcast is scheduled for the same day at 11:00 a.m. Eastern Time, which will include prepared remarks followed by a Q&A session with the executive management team [1]. Accessing the Conference Call - The conference call can be accessed via a webcast link or by calling designated numbers for US and international participants [2]. - Presentation slides will be available on the Investors section of the VerifyMe website on the morning of the call, and the webcast will be archived for 90 days [2].

Core Insights - Syra Health Corp. reported a total revenue of $1.9 million for Q1 2025, reflecting a 6% increase from $1.8 million in Q1 2024, primarily driven by a 261% year-over-year growth in the Population Health segment [6][7] - The gross margin improved significantly to 31.7%, up 14.6 percentage points from 17.1% in the prior year, attributed to a shift towards higher-margin contracts [8][10] - The company achieved a net loss reduction to $472,000 in Q1 2025, compared to a net loss of $1.4 million in Q1 2024, indicating a substantial improvement in operational efficiency [10][9] Financial Highlights - Total revenue for Q1 2025 was $1.9 million, a 6% increase from $1.8 million in Q1 2024 [6][7] - Population Health revenues reached $1.2 million, more than tripling from $333,000 in Q1 2024, contributing to 65% of total revenues [6][7] - Gross profit margin expanded to 31.7%, up from 17.1% in the previous year [8] - Operating expenses decreased by 39% year-over-year to $1.1 million [9] - Adjusted EBITDA improved to ($462,000) from ($1.4 million) in the prior year [9] Operational Highlights - The company secured a $2.5 million contract with a major insurance provider to enhance member health plans [6] - A one-year, $1.5 million contract extension was obtained with the Indiana FSSA NeuroDiagnostic Institute [6] - A $660,000 contract extension was awarded to improve quality and reduce costs through data analysis [6] - Launched specialized content within Syrenity for individuals living with PTSD [6] Management Commentary - The CEO expressed satisfaction with the strong momentum at the start of 2025, highlighting revenue growth and gross margin expansion driven by a focus on higher-margin business units [5] - The company remains committed to operational efficiency and innovative digital health solutions [5] Financial Outlook - Due to ongoing federal budgetary revisions impacting key customers, the company has decided to withdraw its 2025 guidance until more quantifiable changes are available [6]

Core Insights - Nuvalent, Inc. is focused on advancing its pipeline of targeted therapies for cancer, with pivotal data for zidesamtinib and neladalkib expected in 2025 to support New Drug Application submissions [1][2][5] Pipeline and Business Highlights - The company anticipates pivotal data for zidesamtinib in TKI pre-treated ROS1-positive NSCLC in the first half of 2025, with an NDA submission expected by mid-2025 [1][5] - The ALKAZAR Phase 3 trial for neladalkib is set to begin in the first half of 2025, targeting front-line ALK-positive NSCLC [1][6] - Pivotal data for neladalkib in TKI pre-treated ALK-positive NSCLC is expected by the end of 2025 [1][5] Leadership Promotions - Nuvalent has strengthened its leadership team with key promotions: Ruth Adams to Senior Vice President of Clinical Operations, Dr. Joshua Horan to Senior Vice President of Chemistry, and Jessie Lin to Senior Vice President of Corporate Strategy and Portfolio Management [2][12] Financial Results - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $1.1 billion, sufficient to fund operations into 2028 [13][19] - Research and development expenses for Q1 2025 were $74.4 million, while general and administrative expenses were $20.4 million, resulting in a net loss of $84.6 million for the quarter [13][18]

Core Insights - Sphere Entertainment Co. reported a total revenue of $280.6 million for Q1 2025, a decrease of $40.8 million or 13% compared to the same quarter last year [1][2] - The company experienced an operating loss of $78.6 million, which is an increase of $38.2 million or 95% from the prior year quarter [1][2] - Adjusted operating income was reported at $36.0 million, down $25.6 million or 42% year-over-year [1][2] Financial Performance - Sphere segment revenues were $157.5 million, down $12.8 million or 8% from $170.4 million in Q1 2024 [2][4] - MSG Networks segment revenues decreased to $123.0 million, a decline of $27.9 million or 19% from $151.0 million in the prior year [2][12] - Total operating loss for the company was $78.6 million, compared to a loss of $40.4 million in the same quarter last year [2][11] Segment Analysis - Sphere's direct operating expenses increased by $8.2 million or 13% to $70.5 million, primarily due to additional concerts and higher employee compensation [9] - MSG Networks faced a significant drop in distribution revenue, decreasing by $29.9 million, largely due to the absence of revenues from Altice during a non-carriage period [12][14] - Adjusted operating income for the Sphere segment was $13.1 million, a slight increase of $0.2 million or 2% from the previous year, while MSG Networks' adjusted operating income fell to $22.8 million, down $25.8 million or 53% [2][11] Strategic Developments - The company announced new multi-year marketing partnerships with Pepsi and Google, and plans to host multiple corporate events in Las Vegas [5] - Sphere is set to host the 'Unity' electronic dance music event with nine shows scheduled between August and October [5] - MSG Networks is pursuing a refinancing of its credit facilities, which includes a Transaction Support Agreement with lenders to restructure existing debt obligations [19][20] Cash Flow and Balance Sheet - For Q1 2025, net cash provided by operating activities was $6.3 million, a significant decrease from $101.0 million in Q1 2024 [38] - The company reported a net decrease in cash, cash equivalents, and restricted cash of $37.4 million, ending the quarter with $478.2 million [39] - Total assets as of March 31, 2025, were $4.45 billion, down from $4.52 billion at the end of the previous year [36]

Core Viewpoint - Palvella Therapeutics, Inc. is set to report its first quarter 2025 financial results on May 15, 2025, and will host a conference call to discuss these results and provide a corporate update [1][2]. Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare genetic skin diseases that lack FDA-approved treatments [4]. - The company is developing a pipeline of product candidates utilizing its patented QTORIN™ platform, with a primary focus on lifelong serious genetic skin diseases [4]. - The lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently undergoing evaluation in the Phase 3 SELVA clinical trial for microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial for cutaneous venous malformations [4]. Financial Communication - A conference call for investors will take place at 8:30 a.m. ET on May 15, 2025, to discuss the financial results and provide updates on corporate activities [2]. - The call will be accessible via a live webcast and by phone, with a replay available approximately two hours after the call [3].

NORCROSS, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended March 31, 2025. "Overall revenue of $16.7 million in the first quarter exceeded our expectations, reflecting year-over-year total revenue growth of 28%, primarily driven by higher professional services r ...

Core Viewpoint - Caliber (NASDAQ: CWD) will release its first quarter 2025 financial results on May 15, 2025, and will host a conference call to discuss these results [1][2]. Group 1: Financial Results Announcement - Caliber will announce its Q1 2025 financial results after market close on May 15, 2025 [1]. - A webcast/conference call is scheduled for the same day at 5:00 pm ET for interested parties to discuss the results [1]. Group 2: Accessing the Earnings Call - Investors can join the live earnings call by dialing (800) 715-9871 for domestic calls or (646) 307-1963 for international calls, using conference ID 8746759 [2]. - The call can also be accessed online via Caliber's investor relations page [2]. Group 3: Company Overview - Caliber manages over $2.9 billion in assets and has a 16-year track record in real estate management and development [4]. - The company specializes in hospitality, multi-family residential, and multi-tenant industrial sectors, aiming to generate profits in all market conditions [4]. - Caliber's competitive advantage lies in investing in overlooked projects and geographies, supported by an in-house shared services group for better control and visibility [4].

CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipa ...